Glial cell line-derived neurotrophic factor (GDNF) binds to the GDNF family co-receptor a1 (GFRa1) and activates RET receptor tyrosine kinase. GFRa1 has a putative domain structure of three homologous cysteine-rich domains, where domains 2 and 3 make up a central domain responsible for GDNF binding. We report here the 1.8 Å crystal structure of GFRa1 domain 3 showing a new protein fold. It is an all-a five-helix bundle with five disulfide bridges. The structure was used to model the homologous domain 2, the other half of the GDNF-binding fragment, and to construct the first structural model of the GDNF-GFRa1 interaction. Using site-directed mutagenesis, we identified closely spaced residues, Phe213, Arg224, Arg225 and Ile229, comprising a putative GDNF-binding surface. Mutating each one of them had slightly different effects on GDNF binding and RET phosphorylation. In addition, the R217E mutant bound GDNF equally well in the presence and absence of RET. Arg217 may thus be involved in the allosteric properties of GFRa1 or in binding RET.
Introduction
Glial cell line-derived neurotrophic factor GDNF was first described as a trophic factor for midbrain dopamine neurons (Lin et al, 1993) . Later, GDNF and other GDNF family ligands (GFLs: Neurturin, NRTN; Artemin, ARTN; Persephin, PSPN) were shown to be crucial for the development and maintenance of many more neuron populations (Baloh et al, 2000; Airaksinen and Saarma, 2002) . All GFLs signal through receptor tyrosine kinase RET and require a ligand specific co-receptor a (GFRa1 binds GDNF, whereas GFRa2 binds NRTN, GFRa3 binds ARTN and GFRa4 binds PSPN (Jing et al, 1996; Treanor et al, 1996; Buj-Bello et al, 1997; Baloh et al, 1998; Enokido et al, 1998) . Rat GFRa1 gene codes for a cysteine-rich protein with 468 amino acids including secretory and glycosylphosphatidylinositol (GPI)-anchoring signals. The conserved internally homologous cysteine pattern led to the proposal that GFRa1 contained three homologous domains (Suvanto, 1997; Airaksinen et al, 1999; Lindahl et al, 2000) . In this model, the N-terminal domain 1 is linked by a hinge region to a core of domains 2 and 3, which is followed by a C-terminal extension. Recently, a different model with a large central domain was proposed (Scott and Ibáñ ez, 2001) . This model neglects the conserved cysteine patterning in favor of a single large central domain (equivalent to domains 2 and 3 above).
It is widely accepted that RET is activated by homodimeric GFL-induced complex formation with GFRa1 and that the stoichiometry of the signaling complex is GFL 2 -GFRa 2 -RET 2 , but the mechanism of complex formation remains unclear. In one model (Jing et al, 1996) , a dimeric GDNF first binds to either monomeric or dimeric GFRa1 and the GDNF 2 -GFRa1 2 complex then interacts with RET and induces its homodimerization. However, Eketjäll et al (1999) found two classes of GDNF mutants. L114A, D116A and Y120A did not crosslink to GFRa1 but still required GFRa1 to stimulate RET, while mutants D52A and E61A/E62A neither crosslinked to GFRa1 nor stimulated RET phosphorylation. Finally, Cik et al (2000) found a high-affinity (low pM) GDNF-binding site on GFRa1 only in the presence of RET. Both these studies suggest that RET binding to GFRa1 increases the affinity of GFRa1 for GDNF.
GDNF is a cysteine-knot protein and belongs to the transforming growth factor-b (TGF-b) superfamily (Eigenbrot and Gerber, 1997) . Structural studies (Kirsch et al, 2000; Hart et al, 2002; Thompson et al, 2003) have shown that, in the TGF-b superfamily, the mechanism of the receptor activation is based on ligand-induced receptor dimerization. In GDNF as well, one GFRa1-binding site per monomer has been identified (Eketjäll et al, 1999) . The known TGF-b superfamily receptor ectodomain structures (Greenwald et al, 1999; Kirsch et al, 2000; Hart et al, 2002) have mainly b-sheet single-domain folds, while secondary structure predictions suggest that GFRas are mainly a-helical (Suvanto, 1997 , Airaksinen et al, 1999 Scott and Ibáñ ez, 2001) . Therefore, despite similarities in ligand structures, GFLs are likely to interact differently with their cognate GFRa co-receptors.
By preparing both chimeric GFRa receptors and their N-and C-terminal deletion mutants, Scott and Ibáñ ez (2001) mapped GDNF binding to the central region of GFRa1, residues 145-348. They also report that this area is responsible for ligand-independent interactions with RET, although more C-terminal residues (145-365) are needed to support GDNF-induced RET phosphorylation. We present here the crystal structure of rat GFRa1 domain 3 (residues 239-346) and a model of the homologous domain 2 (residues 150-238) (Airaksinen et al, 1999) . These data together have allowed us to construct the first model of the GFRa1 fragment that binds GDNF. On the basis of the model, we investigated potential GDNF-binding surfaces using site-directed mutagenesis of selected surface-exposed amino-acid residues in rat GFRa1. Finally, we analyze available structure-function data for GDNF binding to GFRa1 and subsequent RET activation.
Results
GFRa1 domain 3 structure determination and overall fold We purified and crystallized the rat GFRa1 domain 3 (residues 239-346) fused to N-terminal FLAG and 6His tags. The structure was solved at 1.8 Å resolution using multiwavelength anomalous diffraction (MAD) data collected from a selenomethionine-substituted protein (Table I) . No structural homologs were identified using the program DALI (Holm and Sander, 1993) , suggesting that the protein fold is novel.
Domain 3 forms a bundle of five a-helices with five disulfide bridges ( Figure 1A and B). Helices a2, a1 and a4 form a triangular spiral ( Figure 1B ) and provide hydrophobic residues, including five phenylalanines, to the core of the bundle. The three most buried phenylalanines (Phe263, Phe328 and Phe332) are highly conserved among mouse GFRa sequences (Lindahl et al, 2000) . (Unlike for mouse, not all of the rat GFRas have been sequenced, but for those that have been, the sequence identity between rat and mouse is 98%. Consequently, we used the mouse sequence alignment (Lindahl et al, 2000) to compare the four co-receptors.) Helix a2 is followed by loop 1 ( Figure 1B ) making a turn to a3, which is antiparallel to and packs against helix a2. Helix a5 is an extension to helix a4. A long loop (loop 2) between helices a3 and a4, defining the other side of the triangle, was only partially visible in electron density, and residues 301-308 are excluded. The adjacent cysteines Cys313 and Cys315 are involved in two different disulfides and so divide this loop into a longer one before the cysteines and a shorter one (loop 3) after.
Disulfide bridges (dsb) dsb-1 (243-313), dsb-2 (250-256), dsb-3 (267-285), dsb-4 (277-337) and dsb-5 (315-325) were found in the corners of the triangle defined by helices a1, a2 and a4 ( Figure 1B) . In one corner, the adjacent cysteines Cys313 (dsb-1) and Cys315 (dsb-5) mediate a tie between helices a1 and a4, and the C-terminal end of loop 2 ( Figure 1B ) (see above). The second corner, an a-hairpin turn of helices a1 and a2, is locked by dsb-2. Dsb-3 and -4 form another pair of disulfide bridges in the last corner. Dsb-3 locks the antiparallel helices a2 and a3 together, and dsb-4 bridges the loop 1 and the C-terminal helix a5. The disulfides are all buried and contribute to the domain 3 hydrophobic core. The electron density maps for the cysteines were unambiguous ( Figure 1C) , and no indications of radiation damage were observed. Altogether, the five disulfide bridges make an extensive network. Domain 3 is clearly an independent folding unit, not part of a larger structure as previously suggested (Scott and Ibáñ ez, 2001) .
A survey of the molecular and electrostatic surface of the domain 3 structure identified three relatively hydrophobic patches (H1-H3; Figure 1D and E), which might be involved in interprotein or interdomain interactions. H1 is formed from the partly buried patch of five phenylalanines (see above). H2, consisting of conserved residues Leu286, Tyr289, Pro299, Leu338 and Ile342 (Lindahl et al, 2000) , lies between the ordered part of loop 2 and helix a5 ( Figure 1D ). The disordered residues in loop 2 may cover H2. The third hydrophobic area, H3 ( Figure 1D ), is next to the domain 3 Nterminus. This 20 Å Â 18 Å plateau runs the length of helix a1, is lined by the bottom of loop 2, and includes the residues Leu246 (Pro in GFRa4), Ile255, Ile293, Val296 (Asp in GFRa2) and Trp312 with conserved hydrophobic nature (Lindahl et al, 2000) . H3 is most likely the surface that interacts with domain 2 (see below). GFRa1 has an overall positive charge, but domain 3 is unusual because its calculated pI is 4.5. This is reflected by two areas of negative electrostatic charge. The first area (top right, Figure 1E ) is a band starting from Asp248 (helix a1) and continuing down one face of helix a4 (Asp321, Glu323 and Asp324). The second area (bottom left, Figure 1E ) consists of residues Asp262, Glu270, Glu280 and Asp284 in loop 1 and helices a2 and a3. In the first area, the acidic nature of the neighboring Glu323 and Asp324 as well as the turn sequence (SGN) preceding helix a4 are conserved among the mouse GFRa1-4 sequences (Lindahl et al, 2000) . In the second area, only the acidic nature of residue 280 is fully conserved, while Asp262 is conserved in GFRa1, GFRa2 and GFRa3.
Modeling of GFRa1 domain 2
The structure of domain 3 clearly demonstrates that GFRa1 is composed of three homologous domains, despite some earlier suggestions (Scott and Ibáñez, 2001; Wang et al, 2004) . First, domain 3 forms a compact well-folded structure, with five intradomain disulfide bridges ( Figure 1B) . Second, the presence of five disulfide bridges per domain (four in domain 1) is consistent with the conserved cysteine pattern in GFRa1 as well as in the other GFRas (Suvanto, 1997; Airaksinen et al, 1999; Lindahl et al, 2000) . Third, the predicted domain 2 helices (Airaksinen et al, 1999) have the same positions with respect to the disulfide bridges as the observed helices in domain 3 (Figure 2) . The domain 2 model, residues 150-238, corresponds to domain 3 residues 239-342 and has a hydrophobic core and exposed charged side chains. The modeled helices are referred as helices a1 0 -a5 0 . The domain 2 disulfides are modeled as dsb-A (154-214), dsb-B (161-167), dsb-C (178-192), dsb-D . Regular secondary structure includes, from N-to C-terminus, helices a1 (residues 243-251), a2 (residues 254-266), a3 (residues 279-291), a4 (residues 319-333) and a5 (residues 336-345). Disulfide bridges (dsb-1-dsb-5) are labeled from 1 to 5. (C) Stereo view of the original electron density map after MAD phasing and solvent flipping calculated using 20-2.0 Å data and contoured at 1.2s. The neighborhood of two adjacent disulfide bridges (dsb-1, 243-313; and dsb-5, 315-325) of the final model is shown as a ball-and-stick representation. The disulfide bridges are highlighted with yellow lines. (D, E) Calculated electrostatic potential for domain 3 mapped onto its molecular surface. Positive charge is colored in blue and negative in red. N-terminus (N), hydrophobic patches (H1-H3; see text) representative of the two areas of negative electrostatic charge are labeled. In (D), the view is essentially as in (A), and in (E), the molecule has been rotated 1801 around the vertical axis. The figures were prepared using MOLSCRIPT (Kraulis, 1991) , GRASP (Nicholls et al, 1991) , BOBSCRIPT (Esnouf, 1997) and RASTER3D (Merritt and Bacon, 1997) .
(187-233) and dsb-E (216-221). Domain 2 has a more compact structure than domain 3 as all the three loops are shorter ( Figure 2 ). The long loop 2 is shorter by six residues and large changes also occur in the other two loops. Loop 1 is shorter by four residues, one before and three after Cys187 (corresponds to Cys277 in domain 3 dsb-4; Figure 1B ), abolishing a turn preceding helix a3 0 . The loop 3 seen in domain 3 is not present in domain 2 due to the absence of five residues.
Triple alanine mutations at 224 RRR and 211 MLF in domain 2 affect GDNF binding (Scott and Ibáñez, 2001 ). In the sequence alignment of domains 2 and 3 (Figure 2 ), Arg224 corresponds to Phe328, which is one of the phenylalanines defining the domain 3 hydrophobic core. To avoid the unlikely burial of Arg224, helix a4 0 is interrupted with a bend that brings the Arg224 side chain to the domain surface. However, as the cysteine spacing from Cys221 to Cys233 is conserved (Figure 2 ), the residues following the arginines were modeled according to the corresponding domain 3 atomic coordinates. In the model, all the three arginines are exposed, Arg226 pointing essentially in the opposite direction to Arg224 and Arg225. Consistent with earlier mutation data (Scott and Ibáñez, 2001) , the 211 MLF triplet is close to Arg224. Met211, Leu212 and the nearby Cys214 in dsb-A are buried and seem to form part of the hydrophobic core rather than being involved in GDNF binding. Phe213 is on the surface, 10 Å from Arg224, and therefore might participate in GDNF binding.
Domain 2 is basic due to two large positively charged areas. Arg224 and Arg225 define the first area, along with Arg217, His207 and Lys150 ( Figure 3A ). The second positively charged area spans helix a3 0 with a potential heparinbinding motif (BBBXBBXXB, . Heparin promotes GDNF binding to GFRa1 (Rickard et al, 2003) . Lys168, Lys169, Lys202 and Arg238 are close by. Domain 2 contains only one distinct hydrophobic surface, at the Cterminus of the domain (Ile229, Val230, Val232, Tyr235 and Tyr209). This surface may form the domain 2 interface with domain 3; intriguingly, there appears to be no flexible linker between domain 2 and domain 3 (see below).
A model of the GDNF-binding GFRa1 fragment
A GFRa domain fold has, due to numerous disulfide bridges and a-helices, a well-defined, rigid core between the first and last cysteine residues. The first cysteine residue in the crystal structure of domain 3 is Cys243 and the last cysteine residue in the domain 2 model is Cys233. Thus, the potential flexible region between the domains is at most from 234 to 242. However, the first residue in the domain 3 structure is 239 and the last five domain 2 C-terminal residues (234-238) are easily modeled using the domain 3 coordinates.
Consequently, there appears to be essentially no linker between the domains, consistent with sequence analysis (Airaksinen et al, 1999) . As hydrophobic patches were identified both near the domain 2 C-terminus and the domain 3 Nterminus, we constructed a two-domain GFRa1 model ( Figure 3A ) by hand-optimizing the interactions between these hydrophobic patches ( Figure 3B ). This constitutes a structural model of the GDNF-binding fragment of GFRa1 (Scott and Ibáñ ez, 2001 ).
In the two-domain model, domain 3 Trp312 intercalates between domain 2 Tyr209 and Tyr235 ( Figure 3B ). Among mouse GFRa sequences, Trp312 is conserved, except for Ser in GFRa3, and residue 235 is always hydrophobic (Tyr, Leu or Phe), while Tyr209 is conserved in GFRa1 and GFRa2. Next to Trp312 in domain 3 is a small hydrophobic cleft lined by conserved Leu246 (Pro in GFRa4) and Pro241. Optimization of the hydrophobic interactions at the domain interface places domain 2 Tyr235 into this cleft and suggests putative interactions with Leu246 and Pro241 ( Figure 3B ). Other potential interactions include contacts between domain 2 Val230 and Val232 and domain 3 Val296. Interestingly, the domain 2 side of this interface contains the Arg224 and Arg225 electropositive region that is important for GDNF binding (Scott and Ibáñ ez, 2001) . Below the arginines is Ile229, which does not contribute to the domain-domain interactions but remains exposed. The GDNF-binding site seems to be near the domain 2 and 3 interface and so the hydrophobic areas at the domain interface may also have a role in ligand binding.
The GDNF-GFRa model and site-directed mutagenensis
Since GFRa1 is known to bind GDNF acidic and hydrophobic finger loops (Eketjäll et al, 1999) , the GFRa1 surface involved in these interactions should possess both electropositive and hydrophobic characters. Furthermore, since GDNF binding is not localized to a single domain but to the central part of GFRa1 (Scott and Ibáñez, 2001) corresponding to domains 2 and 3, both domains presumably participate in GDNF binding. Thus, the likely area is at the domain interface, in the neighborhood of the 224 RRR triplet. To confirm the proposal and to test the models experimentally, we mutated several of the GFRa1 residues within the putative GDNF-binding surface and studied GDNF-binding and GDNF-induced RET activation. The mutants chosen were as follows: F213A, R217E, I219Q, R224A, R225A, R226A, I229D (domain 2), and R240A, E280A, Y254A/I255A, R257A/R259A, D262A/E280A, E323A/D324A (domain 3) ( Figure 3A ). As the arginines in 224 RRR point in different directions, not all can be involved in GDNF binding and so single-site mutants should reveal the GDNF-binding direction. Phe213, Ile219 and Ile229 are conserved nearby hydrophobic residues, and Arg217 and Arg240 (domain 3) are nearby basic residues. Tyr254 is at the edge of the hydrophobic patch in domain 3 defining the domain interface and is not conserved among the mouse GFRa receptor sequences Figure 2 Sequence alignment of GFRa1 domains 1, 2 and 3. The cysteines governing the alignment are highlighted in bold. The two amino-acid triplets in domain 2, MLF and RRR, reported to be important for GDNF binding (Scott and Ibáñ ez, 2001 ) are labeled in bold and Italic. The observed domain 3 secondary structure elements and the three loops are shown. The sequence alignment was generated with CLUSTALW (Higgins et al, 1994) . (Lindahl et al, 2000) . The fully conserved Arg257 and Arg259 are located at the beginning of helix a4. Most of the selected residues were mutated into alanines to avoid structural distortion; however, for 229, we chose mutation into aspartic acid, as the effect of I229A might have been difficult to detect.
Biochemical characterization of the GFRa1 variants
The biochemical effects of the mutations were determined in four ways, with different strengths and weaknesses. First, we screened the effect of added GDNF on RET phosphorylation in MG87-RET cells, transfected with wild-type (wt) or mutant GFRa1. The cells were treated with 3.3 nM GDNF or without, and examined for GDNF-induced RET phosphorylation (Figure 4 ). Only I229D did not mediate phosphorylation of RET. A number of active mutants were further analyzed by varying the GDNF concentration from 33 pM to 3.3 nM, and all behaved essentially as wt (see Supplementary Figure 1 , data shown only for wt, R224A and R225A). The RET phosphorylation assays are the most biologically relevant as they show competent signaling. However, in cell lines with low expression levels of RET, and high transient expression levels of the GFRa1 receptor, one can only identify mutants where GDNF binding is completely abolished. Mutants with weakened GDNF binding have also previously been shown to be active in RET phosphorylation assays (Scott and Ibáñ ez, 2001) . From these assays, we could conclude that only Ile229 is involved in GDNF binding and in mediating RET phosphorylation.
Nevertheless, as previous studies (Scott and Ibáñ ez, 2001 ) had shown that 224 RRR was involved in binding GDNF, we decided to study the binding of GDNF using crosslinking and binding assays. In the absence of RET, 1 nM 125 I-GDNF could be crosslinked to wt GFRa1 and to the R217E and D262A/ E280A variants ( Figure 5F ). It could not be crosslinked to I229D, consistent with the RET phosphorylation assay (Figure 4 ), nor could it be crosslinked to F213A, R224A and R225A. The crosslinking assays were however performed at 1 nM concentrations of radioligand, and so we could detect abolished binding only to severely affected mutants. We therefore quantified binding of GDNF to GFRa1 using both Close-up of (C). GDNF residues important for GFRa1 binding (Eketjäll et al, 1999) and making putative interactions with the GFRa1 residues revealed by our mutagenesis are labeled in Italic and shown as a ball-and-stick representation. GDNF Leu118, also binding GFRa Ile229, is omitted for clarity. The figures were prepared with MOLSCRIPT (Kraulis, 1991) , RASTER3D (Merritt and Bacon, 1997) and GRASP (Nicholls et al, 1991) . a cell-based assay and a scintillation proximity assay (SPA) to determine IC 50 values ( Figure 5 ; Table II ; Supplementary  Figure 2) . The results of the latter biophysical technique agree well with the former (Table II) , showing that the cellbased binding data are reliable and accurate.
Our IC 50 value for the competition of GDNF/ 125 I-GDNF binding to wt GFRa1 in the absence of RET (Figure 5A ), 0.92 nM for the cell-based assay and 0.89 nM by SPA (Table II) , is comparable to the previously reported value, 1.9 nM (Cik et al, 2000) . R224A, R225A ( Figure 5B ) and I-GDNF to total lysates of wild-type (WT), mutant GFRa1 receptor and GFP-transfected COS7 cells. The lysates were resolved on a 10% SDS-PAGE and transferred to nitrocellulose membrane and autoradiograph of the membrane is shown. In addition, the lower panel shows anti-FLAG Western blotting (WB) of the same membrane to quantify GFRa1 expression levels. Figure 4 RET phosphorylation in transiently transfected MG87-RET cells. For each mutant, two parallel samples were used. One was unstimulated, and the other was stimulated with 100 ng/ml GDNF. To ensure that the expression of the mutant was the same in both samples, a fraction of each extract was used for direct probing with anti-FLAG antibodies. Thereafter, RET was immunoprecipitated (IP) from the cell extracts, and its phosphorylation was monitored on Western blots with antibodies to phosphotyrosine (P-TYR). The immunoprecipitated samples were reprobed with antibodies to RET to verify equal loading of proteins in both lanes. GFP-transfected cells were included as a negative control, while the wild-type (WT) GFRa1 receptor was included as a positive control. Figure 5C ) did not bind GDNF. F213A bound GDNF ( Figure 5C ) four-fold (SPA) to 12-fold (cell-based assay) weaker than wt (Table II) . This is consistent with the crosslinking results (Figure 5F ), because the concentration of 125 I-GDNF in that experiment was 1 nM, and the binding constants for all these four variants are 11 nM (F213A) or more in the absence of RET in the cell-based assay (Table II and  below) . All the other mutants show essentially wt behavior in the absence of RET (Table II) .
I229D (
As with wt, RET enhances GDNF binding to the F213A variant ( Figure 5C ) by a factor of 3-5 (Table II) . Interestingly, the R217E variant does not bind GDNF more tightly in the presence of RET, although it shows wt behavior in GDNFinduced RET activation (Figure 4 ) and in neurite outgrowth activity in PC6 cells (data not shown). The mutant thus appears not to affect GDNF binding directly, consistent with the model (Figure 3C and D) , but appears to affect the allosteric coupling between GDNF and RET.
Additional binding experiments were performed to determine a putative lower affinity limit for GDNF binding for the R224A mutant. The concentration of 125 I-GDNF (GDNF*) was increased to 1, and 100 nM unlabeled GDNF was used for homologous competition. The R224A mutant alone did not bind GDNF, but coexpression of RET partially restores binding ( Figure 5E ). Assuming a conventional binding curve, that the concentration of wt and R224A protein is the same, that [GDNF*] is 1 nM, that 60 000 counts represent saturation of GFRa1 and so can be used as an estimate of the total concentration of wt, the K d can be crudely estimated using the following ratio: (Eketjäll et al, 1999; Scott and Ibáñez, 2001) showing that RET activation in cells overexpressing receptor can occur despite suboptimal GDNF-GFRa1 interactions.
Docking of GDNF to the GFRa1 model
The structure of GDNF has previously been published (Eigenbrot and Gerber, 1997) , and we docked that to our two-domain model of GFRa1. The previously published mutagenesis data on GDNF (Eketjäll et al, 1999) showed that numerous GDNF residues, when mutated to alanine, affected binding to GFRa1. However, only two mutations in GDNF, E61A/E62A and D116A, completely abolished the binding to GFRa1. Similarly, our data show that GFRa1 mutations R224A and R225A abolish binding to GDNF. Our GFRa1-GDNF model is consistent with these data ( Figure 3D ), as Asp116 of GDNF interacts with the basic Arg224 of GFRa1, while Glu61, rather than the Glu62, of GDNF is close to the Arg225 of GFRa1 ( Figure 3D ). This explains why Glu61, but not Glu62, is conserved among GFLs (Eketjäll et al, 1999 ). This docking model furthermore brings the Leu114 and Leu118 of GDNF in contact with the Ile229 of GFRa1 ( Figure 3D ), while GDNF Leu118 is the closest hydrophobic residue to GFRa1 Phe213. Finally, GDNF Tyr120 also lies in the GDNF-binding pocket between domains 2 and 3. The mutagenesis data and our model are thus consistent.
Discussion
Ligand specificity in GFL-dependent RET signaling is controlled by the interactions between GFLs and the corresponding GFRas. To study these interactions, we have solved the GFRa1 domain 3 crystal structure at 1.8 Å resolution. The structure reveals a novel all-a fold with five disulfide bridges, differing drastically from the other known TGF-b superfamily receptor structures. It serves as a model for other homologous domains (Airaksinen et al, 1999; Lindahl et al, 2000) in the GFRa family, including GFRa2, GFRa3 and GFRa4. Domain 3 atomic coordinates were used to model GFRa1 domain 2, the other half of the ligandbinding fragment, in order to provide new insight into how GDNF might bind to its co-receptor GFRa1. Our mutagenesis data for the first time identify five specific domain 2 residues with effects on GDNF binding and RET phosphorylation. Four residues (Phe213, Arg224, Arg225 and Ile229) are in the GDNF interface, while one, Arg217, clearly is not. The effects of the first four mutations fall into two categories: (1) mediating GDNF-dependent RET phosphorylation (Figure 4, Supplementary Figure 1) despite weakened GDNF binding (F213A, R224A, R225A) or (2) indetectable GDNF binding and RET phosphorylation (I229D). The results reflect the differing sensitivity of binding versus phosphorylation assays; even a minute amount of binding leads to phosphorylation, making RET phosphorylation studies insensitive to mutation (Scott and Ibáñ ez, 2001) . The data confirm the importance of the 224 RRR triplet (Scott and Ibáñ ez, 2001 ), but show that, consistent with the domain 2 modeling, only Arg224 and Arg225 interact with GDNF; Arg226 points away from GDNF and is fully active when mutated into alanine. Similarly, only Phe213 from the 211 MLF triplet (Scott and Ibáñez, 2001) can interact with GDNF in our model, and the F213A variant shows reduced GDNF binding (Table II) . Ile229 is located directly below Arg224 and Arg225. It was the only tested mutant not to support GDNF-induced RET phosphorylation (Figure 4) showing, similarly to GDNF mutagenesis data (Eketjäll et al, 1999) , the importance of hydrophobic residues in GFRa1.
The most interesting mutant is R217E, which binds GDNF as tightly as wt, but does not bind GDNF tighter in the presence of RET (Table II) . What might its role be, given that it is 10-20 Å from the putative GDNF interface on GFRa1 ( Figure 3C )? Although R217E does not support the higher affinity binding of GDNF in the presence of RET, it still activates RET in the presence of GDNF (Figure 4) . It is thus tempting to speculate that Arg217 is part of the GFRa1-RET interface ( Figure 3C ), and that in the mutant, some aspect of the allosteric mechanism of GFRa1 appears not to be normal. (This is different from F213A, R224A and R225A, which display weakened GDNF binding, but which clearly bind GDNF tighter in the presence of RET.) The R217E data indicate that, although GFRa1-RET interactions are necessary for forming the higher affinity GFL-binding complex, they are not crucial for RET activation.
Scott and Ibáñ ez (2001) also found GFRa1 mutants, which did not crosslink to GDNF but nonetheless mediated GDNFinduced RET phosphorylation, and Eketjäll et al (1999) report GDNF mutants, which, despite impaired GFRa1 binding, activate RET normally. Clearly, GDNF-GFRa1 interactions can largely be compromised without losing GDNF-induced RET activation, which explains the cross-talk between the homologous GFLs and GFRas (Airaksinen et al, 1999) . Direct GDNF-RET interactions may be important for RET activation (Eketjäll et al, 1999; Scott and Ibáñ ez, 2001 ); GFRa1 may be a scaffold to hold the GDNF in place to interact with RET. One possible arrangement (Figure 6 ) places the GFRa1s on the outside of the dimeric complex, holding the GDNF by the 'fingers' as in our model ( Figure 3C ). This crossover model is consistent with recent work (Anders et al, 2001 ; Kjaer and Ibáñ ez, 2003) showing that the first cadherin-like domain of RET contains the largest GFRa1 interface, and our model places the two RET tyrosine kinases close to each other, as they need to be. Our structure and mutagenesis data are, however, not consistent with the recent paper by Wang et al (2004) . For instance, the results on the R259A variant differ completely, and the GDNF-binding residues they propose (Arg259, 152 NN and 316 SNS) are both distant from our GDNF-binding site and from each other; they do not form a surface. They also believe that GFRa1 contains a large central domain, comprising our domains 2 and 3, which this work conclusively disproves.
On the basis of our findings, the previously reported GDNF structure (Eigenbrot and Gerber, 1997 ) and the GDNF (Eketjäll et al, 1999) and GFRa (Scott and Ibáñez, 2001 ) mutagenesis data, we propose a molecular model for how GFRa1 binds GDNF ( Figure 3C and D) . In it, the GFRa1 Arg224 and Arg225 interact with the GDNF Asp116 and Glu61, while Ile229 interacts with GDNF Leu114 and Leu118. The latter may also interact with Phe213 after a small structural rearrangement. GFRa1 Arg224 and Arg225, as well as the hydrophobic nature of residue 229, are fully conserved (Airaksinen et al, 1999; Lindahl et al, 2000; Scott and Ibáñez, 2001) , suggesting that these interactions occur in all GFRa-GFL complexes. Our work provides the structural basis for continued exploration of GFRa in the RET-GFRa-GFL system.
Materials and methods

Expression and purification of GFRa1 domain 3
A construct encoding residues 239-346 of mature rat (Rattus norvecigus) GFRa1 and N-terminal FLAG and 6His tags was Figure 6 Schematic diagram of the interaction of GFRa1, RET and GDNF. A (GDNF-GFRa1-RET) 2 symmetrical dimeric complex is shown. Dark gray: the four cadherin domains of RET, numbered 1-4; diagonal lines, the cysteine-rich domain; wavy lines, the tyrosine kinase domains. In light gray (labeled) is the GDNF dimer. In white are the three triangular a-spiral folds of GFRa1. The figure shows the interaction between GDNF, the GFRa1 domain 2-3 cleft (see above) and cadherin domain 1 of RET (Kjaer and Ibáñ ez, 2003) .
subcloned into the pFASTBAC1 (Gibco-BRL)-based baculovirus transfer vector pK503.9 (Keinänen et al, 1998) . Soluble secreted GFRa1 domain 3 was expressed by infection of Sf9 insect cells with baculovirus at high multiplicity. Cells were grown in serum-free SF900II (Invitrogen) medium supplemented with 50 mg/ml gentamycin (Sigma) at þ 271C. At 3 days postinfection, GFRa1 domain 3 was purified from culture supernatants by Ni-chromatography (Ni 2 þ -charged chelating sepharose, Amersham Biosciences). The supernatant was adjusted to pH 7.5 with PBS and Ni 2 þ -resin was added. After 2 h incubation at þ 41C, the resin was washed with PBS with 10 mM imidazole. Protein from an imidazole elution was further purified by a Resource Q anion exchange column (Amersham Biosciences). The column was eluted with a 0-1 M NaCl gradient in 20 mM Tris buffer, pH 8.5. For crystallization, the protein buffer was changed to 10 mM HEPES, pH 7.
For selenomethionine (SeMet) labeling, the expression protocol was modified according to Bellizzi et al (1999) . At 24 h after infection, the insect cells were harvested, washed and transferred to SF900II medium lacking methionine (Invitrogen). Following a 4-h depletion period, the medium was supplemented with 50 mg/ml LSeMet (Calbiochem). The culture supernatant was harvested after additional 48 h and the protein was purified as above.
Crystallography
Crystals of the GFRa1 domain 3 were grown at þ 41C in sitting drops over a reservoir solution of 50 mM MES, pH 6.5, 0.2 M MgCl 2 and 10% (v/v) 2-methyl-2,4-pentanediol (MPD). The drops were prepared by mixing 2 ml of the reservoir solution and 2 ml of the protein solution at 3 mg/ml. The crystals belong to spacegroup P6 1 (a, b ¼ 61.3 Å , c ¼ 65.2 Å ) with one molecule per asymmetric unit and solvent content of 51%. For data collection at À1801C, crystals were frozen in liquid nitrogen with the well solution containing MPD at 20% (v/v) .
MAD data on a selenomethionine derivative were collected to 1.8 Å using the BW7A beamline at EMBL Hamburg Outstation at three wavelengths (Table I ). The remote wavelength data set was used for the final refinement. The data sets were processed with the programs DENZO and SCALEPACK (Otwinowski and Minor, 1997) . CNS (Brü nger et al, 1998) was used to find the single selenium site and to estimate experimental phases at 2.0 Å ( Table I) . The spacegroup was shown to be P6 1 by calculating electron density maps both in P6 1 and P6 5 , and choosing the one that gave clear protein-solvent boundaries. The electron density map obtained upon solvent flipping with CNS was used for initial model building.
Using the automated model-building tools in O (Jones et al, 1991) , the sequence was built for residues 239-300 and 309-346. This model was subjected to iterative rounds of building and refinement in CNS (Brü nger et al, 1998 ). Initial refinement was carried out using bulk solvent correction, torsion angle-simulated annealing and B-factor refinement. Water molecules were added to peaks above 3.7s in the (F o ÀF c ) difference map if they had suitable hydrogen bonding geometry. The final model, with good stereochemistry (Table I) , consists of 100 amino acids, one MPD molecule and 97 water molecules. The N-terminal FLAG and 6His tags, residues 301-308 as well as the side chain of the first residue (239) are not seen in the electron density. PROCHECK (Laskowski et al, 1993) was used to assign secondary structure elements and calculate the Ramachandran plot. Of all the non-Gly/non-Pro residues, 96.5% have main-chain torsion angles in the most favored regions, and there are no residues in the disallowed regions.
Modeling
The domain 3 atomic coordinates were used to model the homologous domain 2 (residues 150-238). The domain 3 and 2 sequences were aligned with CLUSTALW (Higgins et al, 1994) and side chains were changed, according to this alignment, in O (Jones et al, 1991) . Loop lengths were adjusted to correspond to the sequence alignment by deleting domain 3 residues, although 3 residues had to be added in the domain 3 missing loop area. The loop data base in O was used to refine loop structures. The final model was refined in CNS by running an energy minimization step. No constraints were used to allow unfavorable atom contacts and bad geometry to be removed. As expected, the disulfide bridges held the overall fold intact. Acceptable model quality was verified by PROCHECK. The docking of the modeled domain 2 to the domain 3 structure as well as the preparation of the GDNF-binding model was carried out manually in O.
Mutagenesis, chemical crosslinking and RET phosphorylation
Mutant clones of rat GFRa1 with an N-terminal FLAG tag were constructed by overlapping PCR fragment mutagenesis. All clones were sequenced to ensure no undesired mutations were introduced during PCR. Full-length wt and mutant FLAG-tagged GFRa1 proteins were expressed in transiently transfected MG87-RET fibroblast cells (Eketjäll et al, 1999) and expression levels were analyzed by Western blotting using both anti-FLAG (M2, Sigma) and anti-GFRa1 (cProSci Inc.) antibodies. All mutant proteins were produced at levels similar to wt (Figure 4) . The secretion of the completely inactive mutant I229D was verified by biotinylation of cell-surface proteins (data not shown).
For chemical crosslinking, GDNF (PeproTech, Ltd, and a kind gift from Cephalon, Inc.) was enzymatically iodinated by lactoperoxidase (Lindahl et al, 2001) . At 24 h after transfecting COS7 cells with mutant GFRa1 cDNA, cells were washed and incubated with 1 nM 125 I-GDNF in binding buffer (Dulbecco's modified Eagle's medium, 0.2% BSA and 15 mM HEPES, pH 7.2) for 2 h on ice. Cells were then washed again three times with ice-cold PBS. N-hydroxysuccinimide (NHS, Sigma) and ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDAC, Sigma) were added to final concentrations of 20 and 40 mM, respectively, and cells were incubated in PBS, pH 7.4, for 20 min at room temperature. The reaction was quenched with TBS, and cells were collected, washed and lysed in lysis buffer (TBS, pH 7.4, 2 mM EDTA, 1% Nonidet P-40, 1% Triton X-100, 1 mM PMSF and Complete protease inhibitor mixture from Roche Molecular Biochemicals). The lysates were subsequently resolved on a 10% SDS-PAGE and transferred to nitrocellulose membrane for autoradiographic exposures. The same membrane was probed with anti-FLAG antibodies (for GFRa1 detection) to ensure that similar amounts of proteins were loaded onto each gel.
The RET phosphorylation assay was carried out by transiently expressing wt or mutant GFRa1 in MG87-RET cells (Eketjäll et al, 1999) . At 24 h after transfection, cells were starved for 4 h and stimulated with 100 ng/ml (3.3 nM) GDNF (PeproTech, Ltd) for initial screening. Later, dose-dependent RET phosphorylations were carried out with 0.033-3.3 nM GDNF. At 10 min after stimulation at þ 371C, cells were lysed on ice and the lysates were immunoprecipitated with RET antibodies (C-20, Santa Cruz Biotechnology). The precipitated immunocomplexes were resolved on SDS-PAGE, transferred to nitrocellulose membranes and probed with phosphotyrosine antibodies (4G10, Upstate Biotechnology). To ensure that equal amounts of RET were precipitated in each sample, the filters were stripped and re-stained with antibodies to RET. The GFRa1 expression levels were analyzed by Western blotting directly from the crude lysate before the immunoprecipitation of RET. The RET phosphorylation assay was repeated at least twice for each mutant.
GDNF-binding assays
For the cell-based homologous competition binding assay, iodinated GDNF (see above, 50 pM) was applied in binding buffer (DMEM, pH 7.4, 0.5% milk and 0.2% BSA) to COS7 cells transfected with GFRa1 cDNA 24 h before assay. Cells were incubated for 2 h on ice in the presence of unlabeled ligand from 0 to 5000 pM (0 to 50 nM for F213A mutant) and then washed with binding buffer without milk and BSA for four times. Upon lysis with 1 M NaOH, cells were placed in scintillation vials and counted on a 1214 RackBeta (Wallac/LKB) scintillation counter. Three to four runs were performed in parallel and the background level was assessed using RET-transfected cells. For competition assays in the presence of RET, the cells were co-transfected with RET and GFRa1 cDNA at a 1:1 ratio, unlike Cik et al (2000) .
For SPA, soluble rat GFRa1 variant (GenBank TM : AJ002072) and human RET extracellular domain (GenBank TM : X12949; RET ED ) constructs were prepared. The cDNA regions of wt GFRa1 and GFRa1 mutants F213A, R217E, R224A, R225A, R226A, I229D and R257A/R259A coding for amino acids 20-425 were amplified by PCR using primers incorporating 5 0 -NotI and 3 0 -HindIII restriction sites in addition to an N-terminal 6His tag and a stop codon at the 3 0 -end. RET ED construct was prepared by amplifying the cDNA region for amino acids 28-636 by PCR using primers incorporating a C-terminal 6His tag and a stop codon at the 3 0 -end. The resulting products were cloned into the baculovirus vector pK503.9 (Keinänen et al, 1998) , which further added a FLAG tag at the Nterminus. The clones were confirmed by sequence analysis. The wt and mutant GFRa1 were expressed in insect cells (see supplementary Figure 3) and extracted from the medium with Ni 2 þ -resin as domain 3 above. RET ED was expressed similarly (see Supplementary Figure 3 ) and used unpurified. The amounts of GFRa1 and RET ED were estimated by Western blotting against known concentrations of purified domain 3 (data not shown). Binding studies were performed in 96-well plates (HB Isoplate, Wallac) in 200 ml volumes. SPA PVT beads precoated with anti-mouse antibodies (Amersham Biosciences) were first mixed with 10 ng of anti-FLAG (M1, Sigma) antibodies and an equal amount of GFRa1 in TBS, pH 7.4, supplemented with 1 mM CaCl 2 and 1.0 mg/ml BSA. If desired, an excess of RET was added into 10 ml of RET ED medium. The beads were then incubated with 50 pM 125 I-GDNF (see above) in the presence of cold GDNF (Amgen) up to 4 nM (40 nM for F213A). Background levels were defined in the presence of RET ED but omitting the GFRa1 variant from the assay. After 3 h incubation at room temperature, plates were counted in a MicroBeta Trilux scintillation counter (Wallac). Each SPA assay was repeated three times with three or four parallel runs.
The binding data were analyzed by nonlinear regression analysis using Prism 3.02 (GraphPad Prism Software, San Diego, CA) to determine the IC 50 values. As the concentrations of the 125 I-GDNF used in the assays were much less than the IC 50 values obtained, the IC 50 values are approximations of the binding affinities, K d 's. The competition data were fitted according to one-site binding models with the background kept constant.
Coordinates
Coordinates have been deposited in the Protein Data Bank (accession code 1Q8D) for release upon publication.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
